Alain Wynckel

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia

Olivier Hermine, Xavier Mariette, Pierre‐Louis Tharaux et al. · JAMA Internal Medicine · 2020 · 777 citations · Full text

Medicine, Infectious Diseases, Pharmacotherapy +14

Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience

Paul Coppo, Michaël Schwarzinger, M. Buffet et al. · PLoS ONE · 2010 · 415 citations · Full text

Medicine, Hematology, Internal Medicine +9

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

Pierre‐Louis Tharaux, Gilles Pialoux, Arthur Pavot et al. · The Lancet Respiratory Medicine · 2021 · 296 citations · Full text

Veterinary Medicine, Immunology, Pharmacotherapy +14

Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center

Antoine Froissart, M. Buffet, Agnès Veyradier et al. · Critical Care Medicine · 2011 · 291 citations

Medicine, Hematology, Immunology +13

Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients

Mikaël Ebbo, A. Grados, M. Samson et al. · PLoS ONE · 2017 · 250 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17